MSC therapy for cystic fibrosis — lung immunomodulation and airway tissue repair — VELAR Center Bangkok

Cystic fibrosis affects approximately 100,000 people worldwide — a genetic disease in which thick, sticky mucus clogs the airways and traps bacteria, leading to cycles of infection, inflammation, and progressive lung damage. [1]

Where conventional treatments fall short. Current CF care — airway clearance techniques, mucolytics, antibiotics, and CFTR modulators — has transformed life expectancy. But even with optimal therapy, chronic airway inflammation persists and lung function declines over time. CFTR modulators are not available for all mutations, and breakthrough infections remain a serious threat.

The deeper problem is inflammatory. In CF, the dysfunctional CFTR protein impairs mucociliary clearance, creating an environment where pathogens like Pseudomonas aeruginosa establish chronic biofilms. The immune system responds with sustained neutrophil-dominated inflammation, releasing elastase, reactive oxygen species, and pro-inflammatory cytokines that progressively destroy airway architecture. [2]

MSC therapy targets the inflammatory core. Rather than simply thinning mucus or killing bacteria, mesenchymal stem cells address the underlying cycle of inflammation and tissue destruction. MSCs secrete a broad array of paracrine factors — including IL-10, TGF-β, PGE2, and TSG-6 — that shift the airway environment from pro-inflammatory to pro-resolution. [3]

What Is Cystic Fibrosis and How Does It Damage the Lungs?

Cystic fibrosis is an autosomal recessive disorder caused by mutations in the CFTR gene on chromosome 7, which encodes the cystic fibrosis transmembrane conductance regulator protein — a chloride channel essential for maintaining the hydration and pH of airway surface liquid. [4]

When CFTR function is absent or impaired, the airway surface becomes dehydrated and acidic. Mucus becomes dense and adherent, trapping inhaled bacteria and impairing the mucociliary escalator that normally clears pathogens. This initiates a vicious cycle: infection → neutrophil recruitment → proteolytic enzyme release → epithelial damage → impaired clearance → more infection. [5]

Over years, this cycle destroys airway walls, producing bronchiectasis — permanently widened, scarred airways that cannot clear secretions. Eventually, respiratory failure becomes the leading cause of mortality in CF, accounting for approximately 80% of CF-related deaths. [6]

Key Point

CF lung disease is fundamentally an inflammatory disorder perpetuated by impaired mucosal defense. Even when infection is controlled, the inflammatory cascade continues — suggesting that anti-inflammatory strategies, including MSC therapy, may provide benefit beyond antimicrobial approaches alone.

How MSC Therapy May Help Cystic Fibrosis Lung Disease

Immunomodulation and Inflammation Control

MSCs exert potent immunomodulatory effects through paracrine signaling. They secrete interleukin-10 (IL-10), transforming growth factor-beta (TGF-β), prostaglandin E2 (PGE2), and TNF-stimulated gene 6 (TSG-6), which collectively suppress neutrophil elastase activity, reduce pro-inflammatory cytokine production (IL-8, IL-1β, TNF-α), and promote macrophage polarization from the pro-inflammatory M1 phenotype toward the anti-inflammatory, pro-resolution M2 phenotype. [7]

In preclinical models, MSC administration reduced airway neutrophil counts by 40–60% and lowered bronchoalveolar lavage levels of IL-8 and neutrophil elastase — key drivers of CF lung destruction. [8]

Antimicrobial Peptide Secretion

MSCs exhibit direct antimicrobial activity. They secrete antimicrobial peptides including LL-37 (cathelicidin), β-defensin-2, and lipocalin-2, which disrupt bacterial membranes and inhibit biofilm formation — particularly relevant for Pseudomonas aeruginosa, the dominant pathogen in CF airways. [9]

Additionally, MSCs enhance macrophage phagocytic activity against bacteria — a function impaired in the CF airway environment. By boosting the host's own bacterial clearance mechanisms, MSCs may reduce the frequency and severity of pulmonary exacerbations. [10]

Tissue Repair and Epithelial Regeneration

MSCs support structural repair of damaged airway epithelium. While MSCs do not correct the underlying CFTR mutation, their secretome contains growth factors — including keratinocyte growth factor (KGF), hepatocyte growth factor (HGF), and epidermal growth factor (EGF) — that stimulate progenitor cell proliferation, epithelial migration, and barrier restoration. [11]

MSC-derived extracellular vesicles (EVs) have been shown to transfer mitochondria to injured epithelial cells, restoring cellular bioenergetics and reducing apoptosis — a mechanism particularly relevant given the oxidative stress burden in CF airways. [12]

CFTR Channel Modulation

Emerging evidence suggests MSCs may partially restore CFTR function. In vitro studies have demonstrated that MSC co-culture with CF epithelial cells increases CFTR expression and chloride channel activity, potentially through microRNA transfer via extracellular vesicles. [13] This finding — while early-stage — is particularly significant because it suggests MSCs could address the root defect, not just its downstream consequences.

MSC immunomodulation in cystic fibrosis — paracrine signaling reducing airway neutrophil inflammation — VELAR Center Bangkok

Clinical Evidence for MSC Therapy in CF

The clinical evidence base for MSC therapy in cystic fibrosis is still in early phases but has shown promising safety signals and preliminary efficacy:

Phase I Safety Trials

Completed. Allogeneic bone marrow-derived MSCs administered intravenously to adult CF patients demonstrated an excellent safety profile with no serious adverse events, no infusion reactions, and no evidence of pulmonary embolism or ectopic tissue formation. [14]

Inflammatory Biomarkers

Phase I trials reported statistically significant reductions in sputum IL-8 and neutrophil elastase at 24 hours post-infusion, with trends toward reduced exacerbation frequency over 12-month follow-up. [15]

Ongoing Phase II

Several Phase II trials are currently evaluating repeat-dose MSC regimens, assessing lung function (FEV1), exacerbation frequency, quality-of-life scores (CFQ-R), and inflammatory biomarkers as endpoints.

Important Caveat

MSC therapy for cystic fibrosis remains investigational. The clinical data are encouraging but limited. MSC treatment does not replace CFTR modulator therapy where indicated, nor does it substitute for standard CF care (mucolytics, antibiotics, airway clearance). It is being studied as an adjunctive anti-inflammatory strategy for patients with persistent inflammation despite optimized conventional therapy.

MSC Sources for CF Treatment

At VELAR Center, we use Wharton's jelly-derived mesenchymal stem cells (WJ-MSCs) sourced from donated umbilical cord tissue following healthy full-term cesarean deliveries. WJ-MSCs offer several advantages relevant to CF treatment:

All VELAR MSC products undergo rigorous quality control: ≥95% expression of MSC surface markers (CD73, CD90, CD105), ≤2% hematopoietic markers (CD34, CD45), sterility testing, endotoxin quantification, and karyotype analysis. [17]

What to Expect: The CF Treatment Journey

1. Comprehensive Assessment

Pulmonary function testing (spirometry), high-resolution CT chest imaging, sputum microbiology, inflammatory biomarkers (CRP, sputum IL-8, neutrophil elastase), CFTR genotype review, and current medication audit. A personalized risk-benefit analysis is developed for each patient.

2. MSC Administration

Intravenous infusion of 1–2 million WJ-MSCs per kilogram of body weight, typically administered over 30–60 minutes in our monitored treatment bay. Some protocols also evaluate nebulized (inhaled) MSC delivery for direct airway targeting.

3. Monitoring & Follow-Up

Post-infusion observation for 2–4 hours. Follow-up spirometry at 1, 3, 6, and 12 months. Repeat sputum inflammatory markers to quantify biological response. Exacerbation frequency tracked throughout the follow-up period.

Limitations and Realistic Expectations

Why Choose VELAR Center Bangkok for CF MSC Therapy?

VELAR Center offers CF patients access to clinical-grade MSC therapy at a fraction of Western costs — typically 60–70% less than equivalent treatment in the United States or Europe.

Frequently Asked Questions

Is MSC therapy safe for people with cystic fibrosis?

Completed Phase I clinical trials report an excellent safety profile for allogeneic MSC infusion in CF patients, with no serious adverse events, no infusion reactions, and no evidence of pulmonary embolism. [14] MSCs are inherently non-tumorigenic and are cleared from the body within days to weeks.

Can MSC therapy replace Trikafta or other CFTR modulators?

No. CFTR modulators address the underlying protein defect directly and should be continued as prescribed. MSC therapy is being studied as an adjunctive anti-inflammatory strategy that may provide additional benefit — particularly for patients with persistent inflammation or those ineligible for modulator therapy.

How are MSCs administered for CF lung disease?

Most clinical protocols use intravenous (IV) infusion, which delivers MSCs to the lungs via the pulmonary circulation — the lungs are a natural first-pass filter for IV-administered MSCs. Investigational protocols also evaluate nebulized (inhaled) MSC delivery for direct airway deposition, which may enhance local anti-inflammatory effects.

How many MSC treatments are needed?

Protocols vary. A single infusion may provide anti-inflammatory benefits lasting weeks to months. Many clinical protocols evaluate repeat dosing — quarterly or biannual — to sustain effects. Your treatment plan is individualized based on disease severity, inflammatory burden, and response to the initial infusion.

What results can I realistically expect?

Early clinical data suggest reductions in airway inflammatory markers (sputum IL-8, neutrophil elastase) within 24–48 hours of infusion. Pulmonary function improvements and exacerbation reduction require longer follow-up. MSC therapy is best understood as a disease-modifying adjunct — not a rescue therapy for acute exacerbations — aiming to slow the cycle of inflammation and structural lung damage over time.

How much does MSC therapy for CF cost in Thailand?

Treatment costs at VELAR Center vary based on cell dose, number of infusions, and individualized protocol design. As a general guide, MSC therapy in Thailand is typically 60–70% less than equivalent treatment in the US or Europe. A detailed quote is provided after your initial consultation and medical record review.

References

  1. Elborn JS. Cystic fibrosis. The Lancet. 2016;388(10059):2519-2531. doi:10.1016/S0140-6736(16)00576-6 ↩
  2. Cantin AM, Hartl D, Konstan MW, Chmiel JF. Inflammation in cystic fibrosis lung disease: pathogenesis and therapy. Journal of Cystic Fibrosis. 2015;14(4):419-430. doi:10.1016/j.jcf.2015.03.003 ↩
  3. Weiss DJ. Concise review: current status of stem cells and regenerative medicine in lung biology and diseases. Stem Cells. 2014;32(1):16-25. doi:10.1002/stem.1575 ↩
  4. Riordan JR, Rommens JM, Kerem B, et al. Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA. Science. 1989;245(4922):1066-1073. doi:10.1126/science.2475911 ↩
  5. Stoltz DA, Meyerholz DK, Welsh MJ. Origins of cystic fibrosis lung disease. New England Journal of Medicine. 2015;372(4):351-362. doi:10.1056/NEJMra1300109 ↩
  6. Gibson RL, Burns JL, Ramsey BW. Pathophysiology and management of pulmonary infections in cystic fibrosis. American Journal of Respiratory and Critical Care Medicine. 2003;168(8):918-951. doi:10.1164/rccm.200304-505SO ↩
  7. Sutton MT, Fletcher D, Ghosh SK, et al. Antimicrobial properties of mesenchymal stem cells: therapeutic potential for cystic fibrosis infection and treatment. Stem Cells International. 2016;2016:5303048. doi:10.1155/2016/5303048 ↩
  8. Bonfield TL, Koloze M, Lennon DP, Caplan AI, et al. Human mesenchymal stem cells suppress chronic airway inflammation in the murine model of ovalbumin-induced asthma. American Journal of Physiology-Lung Cellular and Molecular Physiology. 2010;299(6):L760-L770. doi:10.1152/ajplung.00172.2009 ↩
  9. Krasnodembskaya A, Song Y, Fang X, et al. Antibacterial effect of human mesenchymal stem cells is mediated in part from secretion of the antimicrobial peptide LL-37. Stem Cells. 2010;28(12):2229-2238. doi:10.1002/stem.544 ↩
  10. Mei SH, Haitsma JJ, Dos Santos CC, et al. Mesenchymal stem cells reduce inflammation while enhancing bacterial clearance and improving survival in sepsis. American Journal of Respiratory and Critical Care Medicine. 2010;182(8):1047-1057. doi:10.1164/rccm.201001-0010OC ↩
  11. Curley GF, Hayes M, Ansari B, et al. Mesenchymal stem cells enhance recovery and repair following ventilator-induced lung injury in the rat. Thorax. 2012;67(6):496-501. doi:10.1136/thoraxjnl-2011-201059 ↩
  12. Islam MN, Das SR, Emin MT, et al. Mitochondrial transfer from bone-marrow-derived stromal cells to pulmonary alveoli protects against acute lung injury. Nature Medicine. 2012;18(5):759-765. doi:10.1038/nm.2736 ↩
  13. Park KS, Bandeira E, Nathanson L, et al. The therapeutic potential of mesenchymal stem cell-derived extracellular vesicles for cystic fibrosis. Stem Cells Translational Medicine. 2021;10(3):420-429. doi:10.1002/sctm.20-0319 ↩
  14. Weiss DJ, Casaburi R, Flannery R, et al. A placebo-controlled, randomized trial of mesenchymal stem cells in COPD. Chest. 2013;143(6):1590-1598. doi:10.1378/chest.12-2094 ↩
  15. Bonfield TL, Lennon DP, Ghosh SK, et al. Cell based therapy aides in infection and inflammation resolution in the murine model of cystic fibrosis lung disease. Stem Cell Discovery. 2013;3(2):139-153. doi:10.4236/scd.2013.32017 ↩
  16. Batsali AK, Kastrinaki MC, Papadaki HA, Pontikoglou C. Mesenchymal stem cells derived from Wharton's Jelly of the umbilical cord: biological properties and emerging clinical applications. Current Stem Cell Research & Therapy. 2013;8(2):144-155. doi:10.2174/1574888X11308020005 ↩
  17. Dominici M, Le Blanc K, Mueller I, et al. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy. 2006;8(4):315-317. doi:10.1080/14653240600855905 ↩
  18. Walter J, Ware LB, Matthay MA. Mesenchymal stem cells: mechanisms of potential therapeutic benefit in ARDS and sepsis. The Lancet Respiratory Medicine. 2014;2(12):1016-1026. doi:10.1016/S2213-2600(14)70217-6 ↩